<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596930</url>
  </required_header>
  <id_info>
    <org_study_id>NL73896.091.20</org_study_id>
    <nct_id>NCT04596930</nct_id>
  </id_info>
  <brief_title>MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma</brief_title>
  <acronym>EMITT</acronym>
  <official_title>MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: In preparation of a randomized controlled trial, the investigators aim to assess&#xD;
      pilot data on technical feasibility and safety of laser interstitial thermal therapy (LITT)&#xD;
      at Radboud University Medical centre and to assess practical feasibility of a randomized&#xD;
      study in patients with primary irresectable glioblastoma, as compared with standard of care.&#xD;
&#xD;
      Study design: Prospective randomized pilot study. Randomization stopped (amendment September&#xD;
      2nd, 2021),&#xD;
&#xD;
      Study population: 20 patients aged &gt;= 18 with radiologically suspected diagnosis of primary&#xD;
      glioblastoma and contra-indication for surgical resection.&#xD;
&#xD;
      Intervention: Patients will be randomized to receive either (i) biopsy and LITT (n=10) or&#xD;
      (ii) biopsy alone (n=10).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inclusion rate of patients meeting the inclusion criteria</measure>
    <time_frame>12 months</time_frame>
    <description>To assess practical feasibility of a randomized study in this patient population, in preparation of a future randomized controlled trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number drop out (informed consent)</measure>
    <time_frame>30 days</time_frame>
    <description>To assess practical feasibility of a randomized study in this patient population, in preparation of a future randomized controlled trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with completed follow-up at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>To assess practical feasibility of a randomized study in this patient population, in preparation of a future randomized controlled trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30-days mortality</measure>
    <time_frame>30 days</time_frame>
    <description>To assess safety of LITT at our center in patients with irresectable glioblastoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with complications</measure>
    <time_frame>3 months</time_frame>
    <description>To assess safety of LITT at our center in patients with irresectable glioblastoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from inclusion to procedure</measure>
    <time_frame>3 months</time_frame>
    <description>To assess feasibility of LITT at our center in patients with irresectable glioblastoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from LITT to adjuvant therapy</measure>
    <time_frame>3 months</time_frame>
    <description>To assess feasibility of LITT at our center in patients with irresectable glioblastoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ablation of 90 percent of the target lesion in at least 70 percent of patients</measure>
    <time_frame>3 months</time_frame>
    <description>To assess feasibility of LITT at our center in patients with irresectable glioblastoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival and progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>To assess preliminary data on survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro quality of life-5D (from 11111, best outcome to 55555 worse outcome)</measure>
    <time_frame>3 months</time_frame>
    <description>To assess preliminary data on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer - BN20 brain module</measure>
    <time_frame>3 months</time_frame>
    <description>To assess preliminary data on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor volume evolution</measure>
    <time_frame>3 months</time_frame>
    <description>To assess tumour volume evolution on MRI at 3 months post-operatively</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>LITT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive biopsy and LITT (n=10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser ablation thermal therapy</intervention_name>
    <description>The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance</description>
    <arm_group_label>LITT arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        In order to be eligible to participate in the study, a patient must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          -  Informed consent, age &gt;18-year-old&#xD;
&#xD;
          -  Supratentorial localization&#xD;
&#xD;
          -  Maximal volume &lt;=70cc on post-contrast T1 MRI&#xD;
&#xD;
          -  Safe trajectory/trajectories possible for ablation of 70% of the tumour, avoiding&#xD;
             eloquent structures or transgression of a ventricle or vessel .&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) &gt;= 70&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        A potential subject who meets any of the following criteria will be excluded from&#xD;
        participation in this study:&#xD;
&#xD;
          -  Contra-indication for general anaesthesia or MRI&#xD;
&#xD;
          -  Lesion &gt;70cc on post-contrast MRI on the day before intervention.&#xD;
&#xD;
          -  Non-glioblastoma diagnosis as per frozen section analysis&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Ter Laan, PHD</last_name>
    <phone>+31621175664</phone>
    <email>mark.terlaan@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilaria Viozzi, MD</last_name>
    <phone>+31623662052</phone>
    <email>ilaria.viozzi1@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

